About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5316006
Allelic
Composition
Slc6a3tm2(tTA)Xz/Slc6a3+
Tg(tetO-COX8A/PstI*)1Ctm/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * C57BL/6J * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc6a3tm2(tTA)Xz mutation (0 available); any Slc6a3 mutation (66 available)
Tg(tetO-COX8A/PstI*)1Ctm mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• mutants at 2 months of age exhibit a decrease in the exploration time in the activity cage, with this reduction lasting the duration of the dark cycle
• at 4 months of age, mutants exhibit an increased latency time to descend a pole from a fixed height, indicating poor motor coordination
• however, mutants show normal rotarod performance
• 4 month of mutants treated with L-DOPA and carbidopa, a common therapy for Parkinson Disease, exhibit improved performance on the pole test and the activity cage

growth/size/body
• mutants gain weight at a slower rate than controls; this slower weight gain is first observed at 2 months of age

homeostasis/metabolism
• mutants show a significant reduction in overall all amount of dopamine at both 4 and 12 months of age compared to controls
• mutants however show an increase in the amount of HVA and DOPA, downstream metabolites of dopamine, indicating altered dopamine metabolism in the striatum
• mutants over 12 months of age exhibit an increase in monoamine neurotransmitters, noradrenaline and serotonin
• mutants over 12 months of age exhibit an increase in monoamine neurotransmitters, noradrenaline and serotonin

nervous system
• at 9 months of age, but not 4 months, mutants exhibit a 60% reduction in TH+ neurons in the substantia nigra, and by 12 months of age, very few TH+ neurons are left in the substantia nigra
• mutants exhibit a reduction in TH+ neurons in the striatum at 4 months of age
• mutants exhibit a reduction in dopamine transporter steady-state levels in the striatum, indicating a reduction of dopaminergic presynaptic terminals in the striatum at 4 months of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Parkinson's disease DOID:14330 OMIM:PS168600
J:178139


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory